Literature DB >> 29250328

Sequence analysis of hepatitis C virus nonstructural protein 3-4A serine protease and prediction of conserved B and T cell epitopes.

Ayesha Naeem1, Yasir Waheed1,2.   

Abstract

The hepatitis C virus (HCV) is a global health issue. The nonstructural protein 3 (NS3)-4Agene of HCV is responsible for serine protease activity. The aim of the present study was to develop a global consensus sequence of HCV serine protease, analyze conserved residues, and predict highly conserved B- and T-cell binding epitopes in the NS3-4A protein. A total of 160 NS3-4A sequences from the six genotypes of HCV were refracted in the current study. The amino acid sequences were aligned to obtain a global consensus sequence. The location of possible B- and T-cell epitopes were predicted in the HCV NS3-4A consensus sequence by employing bioinformatics tools. Despite the high mutation rate of HCV, the functionally important residues are highly conserved. These include residues that form the catalytic triad (His57, Asp81 and Ser139), the S1 and S6 pocket, zinc-binding site (Cys97, Cys99, Cys145 and His149) and the substrate binding groove. The epitopes B1, B8 and B9 are predicted to be ideal candidates for B-cell-based vaccine and are >95% conserved across six major HCV genotypes. The major histocompatibility complex (MHC) class I epitopes, M4, M5, M7 and M10, and MHC class II epitopes, T5, T7 and T10 are ideal epitopes for vaccine development with high antigenicity scores and high conservancy across major HCV genotypes. The predicted B- and T-cell epitopes are ideal targets for vaccine development, and are capable of producing a strong immune response for all major genotypes of HCV.

Entities:  

Keywords:  B-cell epitopes; T-cell epitopes; global consensus sequence; hepatitis C virus; serine protease

Year:  2017        PMID: 29250328      PMCID: PMC5727757          DOI: 10.3892/br.2017.1007

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  13 in total

Review 1.  Review: molecular epidemiology of hepatitis C virus.

Authors:  D B Smith; P Simmonds
Journal:  J Gastroenterol Hepatol       Date:  1997-07       Impact factor: 4.029

Review 2.  Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: Treatment response, side effects and future prospective.

Authors:  Yasir Waheed
Journal:  Asian Pac J Trop Med       Date:  2015-02       Impact factor: 1.226

3.  Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide.

Authors:  J L Kim; K A Morgenstern; C Lin; T Fox; M D Dwyer; J A Landro; S P Chambers; W Markland; C A Lepre; E T O'Malley; S L Harbeson; C M Rice; M A Murcko; P R Caron; J A Thomson
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

Review 4.  Hepatitis C: the clinical spectrum of disease.

Authors:  J H Hoofnagle
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

5.  Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions.

Authors:  R Bartenschlager; L Ahlborn-Laake; J Mous; H Jacobsen
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection.

Authors:  Yasir Waheed
Journal:  World J Virol       Date:  2015-02-12

7.  An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A.

Authors:  C Failla; L Tomei; R De Francesco
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

8.  The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor.

Authors:  M R Eckart; M Selby; F Masiarz; C Lee; K Berger; K Crawford; C Kuo; G Kuo; M Houghton; Q L Choo
Journal:  Biochem Biophys Res Commun       Date:  1993-04-30       Impact factor: 3.575

9.  Development of Global Consensus Sequence and Analysis of Highly Conserved Domains of the HCV NS5B Prote in.

Authors:  Yasir Waheed; Umar Saeed; Sadia Anjum; Mohammad Sohail Afzal; Muhammad Ashraf
Journal:  Hepat Mon       Date:  2012-09-25       Impact factor: 0.660

10.  Estimation of Hepatitis B Virus, Hepatitis C Virus, and Different Clinical Parameters in the Thalassemic Population of Capital Twin Cities of Pakistan.

Authors:  Umar Saeed; Yasir Waheed; Muhammad Ashraf; Usman Waheed; Sadia Anjum; Muhammad Sohail Afzal
Journal:  Virology (Auckl)       Date:  2015-11-05
View more
  4 in total

1.  Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.

Authors:  Santa Olivera; Angel Perez; Viviana Falcon; Dioslaida Urquiza; Dagmara Pichardo; Gillian Martinez-Donato
Journal:  Arch Virol       Date:  2020-02-03       Impact factor: 2.574

2.  Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients.

Authors:  Radwa R El-Tahan; Ahmed M Ghoneim; Hosam Zaghloul
Journal:  Virus Genes       Date:  2020-06-22       Impact factor: 2.332

3.  Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from Terminalia chebula: A Structural Perspective.

Authors:  Vishal S Patil; Darasaguppe R Harish; Umashankar Vetrivel; Subarna Roy; Sanjay H Deshpande; Harsha V Hegde
Journal:  Molecules       Date:  2022-02-05       Impact factor: 4.927

4.  HR9: An Important Cell Penetrating Peptide for Delivery of HCV NS3 DNA into HEK-293T Cells.

Authors:  Sina Alizadeh; Shiva Irani; Azam Bolhassani; Seyed Mehdi Sadat
Journal:  Avicenna J Med Biotechnol       Date:  2020 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.